<DOC>
	<DOCNO>NCT00004087</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver tumor-killing substance without harm normal cell . Peripheral stem cell transplantation may able replace immune cell destroy monoclonal antibody therapy use kill tumor cell . PURPOSE : Phase I/II trial study effectiveness radiolabeled monoclonal antibody plus peripheral stem cell transplantation treat patient metastatic recurrent colorectal cancer pancreatic cancer respond previous treatment .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation Treating Patients With Metastatic Recurrent Colorectal Cancer Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose secondary organ toxicity high dose yttrium Y 90 monoclonal antibody MN-14 ( 90Y-hMN-14 ) plus autologous peripheral blood stem cell rescue patient metastatic recurrent colorectal pancreatic cancer . II . Compare tumor organ dose ratio 90Y-hMN-14 iodine 131 monoclonal antibody MN-14 ( 131I-MN-14 ) patient . III . Determine antitumor effect myeloablative dos 90Y-hMN-14 . IV . Evaluate immunogenicity 90Y-hMN-14 patient . OUTLINE : This dose escalation yttrium Y 90 monoclonal antibody MN-14 ( 90Y-hMN-14 ) , multicenter study . Patients stratify prior radiotherapy ( yes v ) . Patients receive filgrastim ( G-CSF ) subcutaneously day -18 -14 peripheral blood stem cell ( PBSC ) collection day -15 -13 . If adequate number CD34+ cell harvest , bone marrow also collect . Patients receive pretherapy image indium In 111 monoclonal antibody MN-14 ( IN111-MN-14 ) IV day -7 0 . Patients receive 90Y-hMN-14 40 minute day 0 . PBSC reinfused day 7 14 . Patients receive G-CSF SQ blood count recover . Cohorts 3-6 patient receive escalate dos 90Y-hMN-14 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose limit toxicity . Patients follow 1-4 , 6 , 8 , 12 , 24 week , every 6 month thereafter 5 year . PROJECTED ACCRUAL : A total 24-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven metastatic recurrent colorectal pancreatic cancer curative surgery exist Failed least 1 regimen standard fluorouracil base chemotherapy metastatic colorectal cancer gemcitabine pancreatic cancer Autologous peripheral blood stem cell ( PBSC ) bone marrow available Diffuse bone marrow involvement allow : Autologous bone marrow PBSC great 5 % tumor involvement available Tumor site least 2.0 cm diameter confirm pretherapy indium In 111 monoclonal antibody MN14 image CT scan PATIENT CHARACTERISTICS : Age : 18 80 Performance status : Karnofsky 70100 % ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL SGOT great 2.0 time upper limit normal ( ULN ) Renal : Creatinine great ULN Other : No severe anorexia , nausea , vomit No concurrent significant medical complication would preclude compliance Not pregnant Fertile patient must use effective contraception 3 month study No allergy 90YhMN14 PRIOR CONCURRENT THERAPY : Biologic therapy : Prior murine monoclonal antibody allow Chemotherapy : No prior irinotecan At least 4 week since prior chemotherapy recover ( 8 week since nitrosourea , mitomycin 90YhMN14 ) Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy index lesion recover No prior radiotherapy great 25 % red marrow ( pelvic field radiation adjuvant therapy rectal cancer allow ) No prior radiotherapy maximum tolerate dose critical organ ( e.g. , lung , liver , kidney ) Surgery : At least 4 week since major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>